Published: Jun 9, 2026
Written by Klarity Editorial Team
Published: Jun 9, 2026

If you’re a psychiatrist or PMHNP considering telehealth—or already running a telepsychiatry practice—you’ve probably asked yourself: Can I legally prescribe Adderall for ADHD over video? What about benzos for anxiety? Do I need an in-person visit first?
The answer depends on where your patient is located, what you’re prescribing, and whether you’re an MD or NP. Federal DEA rules set the baseline, but state laws often add extra steps—or carve out exceptions for mental health providers.
Here’s what you actually need to know in 2026 to prescribe controlled substances via telehealth without risking your license.
Good news first: As of February 2026, you can still prescribe Schedule II-V controlled substances via telehealth to new patients without an in-person exam—at least through December 31, 2026.
The DEA and HHS extended COVID-era telehealth prescribing flexibilities for the fourth time, preventing care disruptions while permanent rules are finalized. This means:
For existing patients you’ve seen in person at any point (even years ago), there’s no federal restriction on prescribing controlled substances via telehealth. You can manage ongoing ADHD, anxiety, or insomnia treatment entirely remotely.
For new patients you’ve never met in person, you can conduct a video evaluation and prescribe Schedule II-V medications (stimulants, benzos, buprenorphine) under the temporary extension—if it’s medically appropriate and meets the standard of care.
This suspension of the Ryan Haight Act’s in-person requirement has been a lifeline for telepsychiatry. But it’s temporary.
The DEA proposed three new rules in January 2025 that will reshape telehealth prescribing once finalized (likely late 2026):
Psychiatrists treating OUD can prescribe buprenorphine via telehealth (including audio-only) for up to 6 months before requiring an in-person visit. This codifies what many addiction psychiatrists have been doing and removes the X-waiver entirely (already eliminated in 2023).
This is huge for general psychiatry. The DEA will allow board-certified psychiatrists (among a few other specialties) to obtain a Special Telemedicine Prescriber Registration to prescribe Schedule II controlled substances—like Adderall or Vyvanse for ADHD—to new patients via telehealth without any in-person exam.
For Schedule III-V meds (most benzos, some sleep meds), any qualified prescriber can get this registration.
The catch: Online telehealth platforms (like Klarity Health) will need to register with the DEA for the first time, and a national PDMP will track controlled prescriptions across state lines. This adds accountability but also legitimizes telepsychiatry by providing a clear legal pathway.
If a veteran had an in-person exam with any VA clinician, any VA telehealth provider (even in a different state) can prescribe controlled substances remotely. This won’t directly affect private practice, but it signals federal acceptance of telehealth continuity of care.
Timeline: These rules are open for public comment. Once finalized, expect stricter documentation requirements, but also more clarity and legitimacy for telehealth prescribers.
Federal law sets the floor, but state laws can be stricter—and they often are. Here’s what you need to know in six key states:
Here’s what most provider recruitment content won’t tell you: acquiring qualified psychiatric patients is expensive and time-consuming if you do it yourself.
Let’s break down what it actually costs to acquire a patient through traditional channels:
SEO:
Google Ads:
Directory Listings:
Total monthly marketing spend for a solo psychiatrist trying to fill a schedule: Easily $3,000-5,000/month with uncertain results—and that’s before counting staff time to handle and qualify leads, no-show rates from cold leads, and months of testing before finding what works.
Klarity Health uses a pay-per-appointment model (similar to Zocdoc) where you pay a standard listing fee per new patient lead. But here’s the difference:
The economic case: Instead of gambling $3,000-5,000/month on marketing with uncertain ROI, you pay only when a qualified patient books with you. That’s guaranteed ROI vs. marketing risk.
DIY marketing can eventually be cost-effective if you have the budget, expertise, and patience—but for most providers (especially those starting out or scaling), a platform that handles patient acquisition removes the risk entirely.
Regardless of state, here’s what every telepsychiatry prescriber should be doing in 2026:
Through December 31, 2026: Yes, under the DEA’s temporary extension—if you’re licensed in the patient’s state and it’s clinically appropriate.
After DEA’s final rules: Likely yes, if you’re a psychiatrist and obtain the proposed Special Telemedicine Registration. Check state law too (e.g., Texas NPs still can’t).
Not under current federal law through 2026. Once permanent rules take effect, psychiatrists may be able to continue telehealth-only care with the special registration. Buprenorphine patients would need an in-person visit after 6 months.
Best practice: For high-risk patients (substance use history, complex polypharmacy), consider requiring or strongly recommending at least one in-person visit for safety.
You need a license in the new state to continue treating them. Interstate compacts (IMLC for MDs, some states for NPs) can help speed this up. Otherwise, you’ll need to refer them to a local provider or pause care while you obtain licensure.
For established patients: Generally acceptable if clinically appropriate (e.g., routine follow-up for stable patients).
For new patients or controlled substances: Not advisable except for buprenorphine (DEA explicitly allows audio-only for OUD treatment). Use video for initial evaluations and any time you’re prescribing Schedule II-IV meds.
State medical boards can discipline you (license suspension, fines). DEA can revoke your controlled substance registration. Insurance plans may deny claims or audit you. Worst case: criminal charges for illegal prescribing.
The stakes are real. When in doubt, consult your state board or a healthcare attorney.
If you’re serious about building or scaling a telepsychiatry practice in 2026:
Get licensed in your target states (consider IMLC if you’re an MD and want to practice in multiple states)
Understand your scope limits (especially if you’re an NP—state laws vary wildly)
Implement compliance systems (PDMP checks, e-prescribing, documentation templates)
Calculate your real patient acquisition costs (most providers are shocked when they add up all the hidden costs of DIY marketing)
Consider platform economics (paying per qualified patient vs. gambling on marketing spend)
For many psychiatrists and PMHNPs, joining a platform like Klarity Health solves the patient acquisition problem while you focus on what you do best—treating patients. You get:
The alternative: Spend months building SEO, burning cash on Google Ads, and competing with hundreds of providers on directory sites—all while managing a solo practice and keeping up with changing regulations.
Most providers who’ve tried both will tell you: the DIY path looks cheaper on paper until you factor in the opportunity cost of all those hours spent on marketing instead of seeing patients.
Yes, DEA rules are getting more structured. Yes, state laws vary. But that’s actually good news for legitimate telepsychiatry providers.
The wild west phase of telehealth (where some platforms overprescribed stimulants with minimal oversight) is ending. What’s replacing it is a system where psychiatrists and PMHNPs who follow the rules have clear, legal pathways to deliver remote care.
If you’re doing thorough evaluations, documenting appropriately, and staying within your scope of practice, you have nothing to worry about. In fact, you’re better positioned than ever—because demand for psychiatric care is at an all-time high, and patients have fully embraced telehealth.
The question isn’t whether you can practice telepsychiatry legally. The question is whether you want to spend your time marketing or treating patients.
Klarity Health connects psychiatrists and PMHNPs with pre-qualified patients seeking mental health care—no upfront costs, no marketing spend, no gambling on SEO or Google Ads.
You set your schedule. We handle everything else.
Explore joining Klarity’s provider network → [Learn more about becoming a Klarity provider]
HHS Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026) – www.hhs.gov
DEA Press Release: ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Care’ (January 16, 2025) – www.dea.gov
Florida Statutes §456.47: Use of Telehealth to Provide Services (2025 edition) – www.leg.state.fl.us
Akerman LLP: ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth’ (March 2023) – www.akerman.com
Texas Medical Board: Prescriptive Authority FAQs (Updated 2024) – www.tmb.texas.gov
Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. State and federal regulations change frequently. Always consult your state medical/nursing board and legal counsel for guidance on your specific situation.
Find the right provider for your needs — select your state to find expert care near you.